UNSPSC 51172170: Drotaverine hydrochloride

This classification denotes an antispasmotic agent with the molecular formula C24H31NO4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 24ZVH4C669, chemically known as 1-benzyl-3,4,6,7-tetraethoxy-1,2,3,4-tetrahydroisoquinoline but more generally known as drotaverine hydrochloride, which bears US NIH Compound Identifier 1712095. European Medicines Agency schedules Drotaverine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01843MIG.

Most nations, for tariff and trade purposes, schedule drotaverine hydrochloride under HS 29334990 and SITC 51575. As of Q4 2014, DROTAVERINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Drotaverine hydrochloride bears US NLM NCI C97980. SMILES: CCOC1CCC(CC1OCC)/C=C\2/C3CC(C(CC3CCN2)OCC)OCC.CL.

UNSPSC 51172170 Drotaverine hydrochloride is a Commodity code encompassing pharmaceutical active pharmaceutical ingredients and finished-dose medications procured through state and local health agencies, correctional departments, and cooperative purchasing alliances. State and local governments buy under this code primarily through multi-jurisdictional pharmaceutical supply contracts and direct acquisition for correctional health services, including prescription fulfillment, offender medical testing and screening programs, and generic medication distribution to public facilities. The issuing bodies include state health and human services commissions, county correctional and supervision departments, and multistate cooperative purchasing organizations that aggregate demand across state agencies and local government entities.

The recent opportunities show activity concentrated in Texas and the Upper Midwest. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and wholesaler channels. Collin County Community Supervision and Corrections Department posted RFP 2026-327 on July 9, 2026 (due July 23, 2026) for offender specimen collection and drug testing services, with an estimated contract value of $600,000 and a two-year term commencing September 1, 2026 with three optional one-year renewals, requiring SAMHSA-, TX DPS-, or CAP-certified lab services for approximately 25,031 annual tests. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 (due March 26, 2026) for generic multi-source pharmaceuticals and OTC products to be distributed across state and local government facilities in Minnesota and Oregon, effective July 1, 2026, with incumbent contracts extended through June 30, 2028. These recent solicitations reflect demand for both specialty testing pharmaceuticals in correctional settings and broad-based generic medication supply through cooperative purchasing mechanisms.